World Health Organization (WHO), International Agency for Research on Cancer (IARC). GLOBOCAN 2012 v1.0: Estimated cancer mortality, incidence and prevalence worldwide in 2012  http://globocan.iarc.fr Accessed July 21, 2017

Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69:438–47  https://doi.org/10.1016/j.eururo.2015.10.024

Eylert MF, Hounsome LS, Persad RA, et al. Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality. J Clin Urol. 2014;7:90–8  https://doi.org/10.1177/2051415813492724 ­­

National Cancer Institute (NCI) Surveillance, Epidemiology and End-Results Program (SEER). Cancer Stat Facts: Bladder Cancer  https://seer.cancer.gov/statfacts/html/urinb.html Accessed July 21, 2017

Zehnder P, Studer UE, Skinner EC, et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int. 2013;112:E51–8  https://doi.org/10.1111/bju.12215

Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315–30  https://doi.org/10.1007/BF03262330

Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006;68:549–53  https://doi.org/10.1016/j.urology.2006.03.062

Sangar VK, Ragavan N, Matanhelia SS, et al. The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005;95:59−63  https://doi.org/10.1111/j.1464-410X.2005.05249.x

Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022  https://doi.org/10.1038/nrdp.2017.22

Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev. 2017;54:58–67  http://dx.doi.org/10.1016/j.ctrv.2017.01.007

British Association of Urological Surgeons (BAUS), Section of Oncology  https://www.baus.org.uk/professionals/baus_business/data_audit.aspx

Lyratzopoulos G, Abel GA, McPhail S, et al. Gender inequalities in the promptness of diagnosis of bladder and renal cancer after symptomatic presentation: evidence from secondary analysis of an English primary care audit survey. BMJ Open. 2013;3.pii: e002861  https://doi.org/10.1136/bmjopen-2013-002861

Gore JL, Lai J, Setodji CM, et al; Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a SEER-Medicare analysis. Cancer. 2009;115:988−96  https://doi.org/10.1002/cncr.24052

Schrag D, Hsieh LJ, Rabbani F, et al. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003;95:588−97  https://doi.org/10.1093/jnci/95.8.588

Hollenbeck B, Ye Z, Dunn RL, et al. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst. 2009;101:571−80  https://doi.org/10.1093/jnci/djp039

Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. Geneva, Switzerland: World Health Organization; 1973

Tumours of the urinary system. In: Eble JN, Sauter G, Epstein Jl, Sesterhenn I, eds. World Health Organization classification of tumours of the urinary system and male genital organs. Lyon, France: IARC Press; 2004; 89−158  http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb7/ Accessed July 23, 2017

Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49;466−77  https://doi.org/10.1016/j.eururo.2005.12.031

Institute of Cancer Research, United Kingdom. Investigating bladder chemotherapy instead of surgery for low risk bladder cancer (CALIBER). ClinicalTrials.gov Identifier: NCT02070120  https://clinicaltrials.gov/ct2/show/NCT02070120 Accessed July 22, 2017

Lewis R, Maynard L, Catto J, et al; CALIBER Trial Management Group. Recruitment aids for a phase II randomised trial in low risk bladder cancer. Eur J Surg Oncol. 2016;42:S244  https://dx.doi.org/10.1016/j.ejso.2016.07.104

Holmäng S, Hedelin H, Anderström C, et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol. 1999;162:702−7

Linton KD, Rosario DJ, Thomas F, et al. Disease specific mortality in patients with low risk bladder cancer and the impact of cystoscopic surveillance. J Urol. 2013;189:828−33  https://doi.org/10.1016/j.juro.2012.09.084

Prout GR Jr, Barton BA, Griffin PP, Friedell GH; National Bladder Cancer Group. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol. 1992;148:1413−9

Rieken M, Xylinas E, Kluth L, et al. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. Eur Urol. 2014;65:201−9  https://doi.org/10.1016/j.eururo.2013.08.034

Thomas JS, Crew J. Active surveillance for bladder cancer. Oncol News. 2011;6:88−90

Mariappan P, Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol. 2005;173:1108−11  https://doi.org/10.1097/01.ju.0000149163.08521.69

National Institute for Health and Care Excellence (NICE). Bladder cancer: diagnosis and management: NICE guideline [NG2]. London, UK: NICE; 2015  https://www.nice.org.uk/guidance/ng2 Accessed July 22, 2017

Thomas F, Rosario DJ, Rubin N, et al. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm? Cancer 2012;118:5525−34 https://doi.org/10.1002/cncr.27587